rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis.
Status: Not yet recruiting

1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination/Orthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination/CBCT approach on the oral health status in IE patients.

Thus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination/CBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients hospitalized for definite IE according to the 2015 ESC classification, whatever the IE responsible microorganism; Patients with a stable clinical state compatible with the performance of an OPT and a CBCT during his/her initial hospitalization for acute IE management; Patients whose life expectancy is expected to be longer than 6 months; Patients who agree to visit the dental department of the hospital to carry out OIF eradication; Patients over 18 years old; Patients affiliated to a Social Security or a health insurance scheme; Patients who have given informed consent to participate to the study.  Exclusion Criteria:  OPT or CBCT already performed before the inclusion of the patients in the study and available for the investigator during the patient's hospitalization. Medical contraindications to perform OPT or CBCT imaging; Absence of microbiologic identification of the IE responsible microorganism; Pregnant or breastfeeding women; Patients under 18 years old; Patients unable to give informed consent to participate to the study (under trusteeship, guardianship and legal protection). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult
P200TxE Diseased Eye Image Collection
Status: Recruiting

The primary objective is to collect images on the P200TxE device in diseased eyes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female subjects 22 years of age or older who have full legal capacity to subject on the date the informed consent is signed; Subjects who can follow the instructions by the clinical staff at the clinical site; Subjects who agree to participate; Subjects who have been diagnosed with retinal pathology and/or glaucoma that affects the posterior pole region including the macula and/or optic nerve.  For glaucoma subjects:  a. Glaucoma subjects who have a history of visual field loss and RNFL or optic nerve changes.  Exclusion Criteria:  Subjects unable to tolerate ophthalmic imaging; Subjects with ocular media not sufficiently clear to obtain acceptable images. - HealthyVolunteers: No - Gender: All - MinimumAge: 22 Years - StdAgeList: Adult, Older Adult
Assessing the Gut Microbiome and Its Association With Pediatric Stress and Cognition
Status: Recruiting

Using a metabolomics approach in combination with eye-tracking data, this research study proposes to gather evidence from two interrelated body systems (gut and brain) in order to assess how the microbiome is involved in stress modulated symptoms in children with autism and children exposed to repeated stress in comparison to a control group.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Children diagnosed with Autism Children with neurotypical development Children in foster care Children in homeless shelters Children 4-7 years old Must be able to watch a short video Must be able to consume children's powder probiotics for 4 weeks  Exclusion Criteria:  Children younger than 4, and older than 7.9 years old. Inability to watch a screen severe cognitive impairment - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 4 Years - MaximumAge: 95 Months - StdAgeList: Child
Efficacy and Safety of Nexpowder™ for Non-variceal, Upper Gastrointestinal Bleeding
Status: Recruiting

The purpose of this pilot clinical trial is to confirm the efficacy and safety of Nexpowder™ for hemostasis in pilot cohort of patients with NVUGIB in Singapore

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Males or females aged over 21 to 75 years Patients with confirmed nonvariceal, upper gastrointestinal bleeding Patients who voluntarily agree to the clinical trial with informed consent Patients who willing and able to comply with the study protocol  Exclusion Criteria:  Patients with an uncorrected coagulation disorder (PLT<50*109/L, INR>2) Patients who are known to be pregnant or in lactation Patients who have received another endoscopic treatment for the same part of the body within the days preceding the study Patients for whom endoscopic treatment is prohibited due to comorbidity Patients for whom the 30-day follow-up period is impossible Patients who have participated within the past month in other related clinical trials that could affect the results of the study Other cases in which participation in the study is judged inappropriate by the investigators - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Kinesiological / Dietary Supplement Intervention in Knee Osteoarthritis
Status: Not yet recruiting

The goal of this clinical trial is to assess the effectiveness of dietary supplement combined with exercise in managing knee osteoarthritis (KOA). The main questions it aims to answer are:

Is adding a dietary supplement to exercise additionally effective in managing KOA?
Is adding exercise to the dietary supplement additionally effective in managing KOA?

Participants will be given in three groups:

Real dietary supplement alone
Real dietary supplement with exercise
Placebo dietary supplement with exercise

Investigators will compare groups 1 and 2, or 2 and 3, to answer the research questions.

The hypothesis is that participants who receive the dietary supplement along with exercise will experience greater reduction in pain level, improved physical function, and enhanced quality of life compared to those who receive a placebo combined with exercise or dietary supplement alone.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  knee osteoarthritis of one or both knee severity of knee osteoarthritis based on Kellgren-Lawrence radiographic grade 1-3  Exclusion Criteria:  Age <55 years Kellgren & Lawrence grade 4 of knee osteoarthritis Acute knee injuries within the last 6 months Knee pain not associated with knee osteoarthritis History of knee or hip endoprosthesis Surgery on the back, hip, knee, ankle, or foot within the last 12 months Health issues or musculoskeletal limitations affecting strength training and mobility more than knee pain (e.g., lower back pain, hip pain) Neurological conditions (Alzheimer's disease, Parkinson's disease, metabolic diseases affecting the nervous system) Muscular or joint diseases/injuries affecting lower limb function (e.g., hip and/or ankle osteoarthritis, sprains, fractures) Internal medical conditions (cardiovascular, pulmonary, oncological, diabetes with late complications - diabetic foot, neuropathies) affecting physical performance Stroke or similar condition with consequences on motor skills and/or cognition (inability to provide consent) Balance disorders, known vestibular system impairment Body Mass Index > 32 Structured strength training exceeding 30 minutes per week Corticosteroids and/or hyaluronic acid (intra-articular) use in the last 3 months Individuals taking joint health dietary supplements, like glucosamine, chondroitin, or collagen, will need to halt use for at least 14 days before measurements to avoid affecting study outcomes - HealthyVolunteers: No - Gender: All - MinimumAge: 55 Years - StdAgeList: Adult, Older Adult
Stress-reducing Intervention in Urothelial Carcinoma
Status: Recruiting

The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in neoadjuvant setting followed by local therapy (standard of care, SOC) compared to SOC alone.

Eligibility:
- EligibilityCriteria: Inclusion criteria:  Patients older than 18 years. Evidence of muscle-infiltrating urothelial bladder carcinoma (including variants) by biopsy. No prior chemotherapy. No previous malignancy, except for basal-cell carcinoma of the skin within last 5 years. Adequate renal functions: measured or calculated (by Cockcroft formula) creatinine clearance > 60 ml/min. Absolute granulocytes count 1,500/mm3 or higher, platelets 100,000/mm3 or higher, bilirubin 1.5x the upper limit of normal value and lower. Adequate liver functions. Basic computer skills. Signed informed consent.  Exclusion criteria:  Diabetes mellitus with symptomatic neuropathy. Using antiarrhythmic drugs, opiates and/or antidepressants. Implanted permanent pacemaker (PPM). Human Immunodeficiency Virus (HIV) infection. Not fitting inclusion criteria. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Status: Not yet recruiting

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Willingness to comply with all study procedures and availability for the duration of the study Willing and able to provide informed consent Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals Documented diagnosis of alcohol-related liver disease (ALD) (per protocol) Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record.  No alcohol use treatment within the past 1 month including, but not limited to:  Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use. Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery) Community-based church support groups primarily focused on alcohol abstinence or reduction in use. Residential (inpatient) alcohol treatment Intensive outpatient programs Any telehealth version of the above options Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud. Ability to speak and comprehend English  Exclusion Criteria:  Unable to provide voluntary informed consent for any reason Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score >=10 on the Short Blessed Test for cognitive impairment. Unable to read or understand English Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine Any other medical condition or circumstance that precludes safe and meaningful participation in the study History of nonadherence to previous clinical or research studies - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
On the ICC's Path: a Prevalence Study
Status: Not yet recruiting

The number of trailers is growing all the time, and TRu seems to be a risky activity for the ankle joint. Ankle sprains can lead to significant health consequences, as in the case of chronic ankle instability.

However, there are no studies informing of the prevalence of chronic ankle instability in trail running. The aim of this study is therefore to take stock of chronic ankle instability in trail running in France.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Trail Running Ultra Trail Running runners Having participated́ in at least one Trail Running or Ultra Trail Running competition in their lifetime. Over 18 years of age (adult participants)  Exclusion Criteria:  Adults protected under Article L1121-8 of the French Public Health Code Minors Adults unable to give consent - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Adult Trail Running racers who have participated in at least one Trail Running competition in their lifetime. Subjects will be recruited via an online questionnaire distributed through various French Trail Running organizations and social networks. - SamplingMethod: Probability Sample
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE（PATH-STROKE）
Status: Recruiting

Objectives of Study:To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic cerebral infarction under the guidance of platelet aggregation function.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged from 18 to 80 years; Patients with non-cardiogenic cerebral infarction WHO meet the definition of stroke, who have been ruled out hemorrhagic stroke by head CT or MRI examination and identified as ischemic stroke; The onset of first stroke >=1 month; mRS Score <=2 points; Mab platelet therapy with aspirin 100mg qd for >=14 days; Informed consent signed by the patient or legal representative.  Exclusion Criteria:  History of gastrointestinal bleeding, intracranial bleeding, and other hemorrhagic diseases; Contraindications or intolerances to the use of antiplatelet therapy drugs; Patients with severe heart, lung, liver and renal insufficiency and with serious co-existing diseases (such as tumor, chronic airflow disease, severe dementia, and severe heart failure; Poor compliance, unable to cooperate with the completion of research requirements. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Study of Natural Course Progression of Diabetic Retinopathy
Status: Recruiting

The goal of this observational study is to observe the formation and development of the non-perfusion area of diabetic retinopathy in the posterior area of the retina in type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and Optos 7 field of vision with mild than severe NPDR, and no other exclusion indicators.The main questions it aims to answer are whether posterior retinal non-perfusion area occurs earlier than peripheral non-perfusion area and whether the rate of non-perfusion area expansion is a risk factor for the progression of diabetic retinopathy.

Participants will have protocol-specific follow-up examinations at 1, 2, 3, 4, and 5 years (± 3 months). Additional visits are made as required by the study and the patient's condition.

The contents of follow-up examinations are:

History of other diseases, medications being used, eye diseases, surgeries, treatments, height, weight, and blood pressure.

Best corrected vision, logarithmic visual acuity chart. Tupai OCTA, 24×20mm range, 6×6mm range scan. Optos fundus imaging, color and no red light images. Fundus fluorescence angiography (only preliminary examination for the first time found mild to moderate NPDR patients, who have been angiographed in the past, only at the 5th year, or as required by the condition).

Glycosylated hemoglobin. Creatinine, urea, glomerular filtration rate. Total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol.

Urinary microalbumin/urinary creatinine ACR. Microvisual field.

Eligibility:
- EligibilityCriteria: Inclusion criteria:  Patients with type 2 diabetes aged 18-75 years Can cooperate with the inspection and sign the informed consent There are no other eye diseases that cause retinal neovascularization There is no known substantial media haze that would hinder fundus image acquisition No history of fundus laser treatment or no possibility of laser treatment expected within six months No previous history of intravitreal drug injection, and no intravitreal drug injection is expected in the next 6 months Macular edema without diabetes (Zeiss OCT women < 290µm, male < 305µm; OCT female in Heidelberg is < 305µm, and for males < 320µm) In the field of visual field of clinical mydriasis and Optos photo 7 field of view, DR Lesions were less severe than NPDR No history of eye surgery  Exclusion criteria:  Patients with kidney failure. History of systemic anti-VEGF therapy within the last month. Follow-up is expected to be difficult or patients from other provinces have traction retinal detachment; The patient has a history of allergy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and Optos 7 field of vision with mild than severe NPDR, and no other exclusion indicators. - SamplingMethod: Non-Probability Sample
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
Status: Not yet recruiting

Dental pain, a common issue in stomatology, requires a multifaceted treatment approach. This study explores the efficacy of combining Ibuprofen with curcumin and liquorice root supplements for managing postoperative dental pain. Curcumin, known for its antioxidant and anti-inflammatory properties, along with liquorice root, may enhance pain relief beyond conventional NSAIDs like Ibuprofen. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety and effectiveness of this combination therapy in adults undergoing the removal of impacted third molars. Participants, aged 18-85, were divided into groups receiving different doses of Ibuprofen and curcumin with liquorice root, compared to a control group receiving Ibuprofen and placebo. The primary outcome is the sum of pain intensity differences over 8 hours, with secondary outcomes including total pain relief and the occurrence of any adverse events. The anticipated sample size, considering a 20% dropout rate, is 264 participants, ensuring the study is powered to detect significant differences in pain management efficacy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Removal of 2 to 4 impacted third molars  Exclusion Criteria:  Pregnancy or breastfeeding Ibuprofen contraindications. Allergy to any of the intervention components. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
NewGait: A Low-Cost Rehabilitation System to Improve Post-Stroke Gait (Biomechanical Adaptations)
Status: Recruiting

An affordable and easy to use gait-assistive device for stroke survivors to use at home is yet to be developed. This study is intended to modify the current design of the NewGait device to specifically work for stroke survivors based on feedback from patients and clinicians. Consequently, conducting a short-term biomechanical gait study is planned to determine the usability and functionality of the NewGait device compared to other comparative devices.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Unilateral cortical or subcortical stroke Chronic stroke (≥ 6 months) At least 6 months following their first unilateral stroke Able to walk independently with/without assistive devices for 5-10 mins (~150m) No significant cognitive deficits as determined by the Mini Mental State Examination (MMSE) score (score≥ 22)  Exclusion Criteria:  Cerebellar stroke Traumatic or vascular brain injury History of unstable heart condition, uncontrolled diabetes/hypertension History of a recent lower-extremity trauma or fracture History of a recent significant orthopedic or neurological conditions that could limit walking ability (e.g., multiple sclerosis, total knee replacement) Documented history of significant spatial neglect ankle joint contractures or significant spasticity in the lower limbs History of a recent Botulinum Toxin (Botox) injection to the lower-extremity muscles (≤ 3 months) Pregnant or actively planning to become pregnant (self-reported)- Inability to communicate or unable to consent - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Multi-center Study on Comprehensive Diagnosis and Treatment of Lower Limb Bone Defect Based on Three-dimensional Printing Technology
Status: Recruiting

The clinical diagnosis and treatment of lower limb bone defect is a difficult problem in orthopedics. The traditional treatment has the shortcomings of long treatment period, no weight bearing in the early stage of the limb, weak mechanical strength, many complications, and difficulty in repairing deformed and large segment bone defects around the joint. The Orthopedics Department of Peking University Third Hospital, the lead unit of this study, developed the TCBridge system based on three-dimensional (3D) printing technology in the early stage, which is the first approved 3D printing lower limb long bone defect repair system in China. The system can achieve personalized and accurate repair of lower limb bone defects, and ensure patients to carry out limb weight and functional exercise safely in the early stage after surgery. On this basis, this study will establish a multi-center clinical case cohort to achieve accurate comprehensive diagnosis and treatment of lower limb bone defects, benefiting patients and contributing to society.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with traumatic lower limb bone defect; Infected lower limb bone defect patients; Patients with neoplastic lower limb bone defect; The above reasons caused bone defects of more than 5CM at least 18 years of age; Sign an informed agreement and join the study cohort voluntarily.  Exclusion Criteria:  Patients who do not agree to the use of 3D printed microporous titanium alloy prostheses; Patients who cannot tolerate surgery; the subjects cannot comply with the follow-up or affect the scientific and integrity of the study; Other patients who were not suitable for inclusion as assessed by clinicians. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with lower limb defects - SamplingMethod: Non-Probability Sample